Table IV.
Clinicopathological features of 35 patients whose high-grade STS tumors were subjected to immunohistochemical analysis.
| Item | Total (n=35) | Good prognosis group (n=15) | Poor prognosis group (n=20) | P-value |
|---|---|---|---|---|
| Age (years, mean ± SD) | 66.2±12.5 | 62.3±9.7 | 67.9±13.9 | 0.275 |
| Sex | 0.182 | |||
| Male | 16 | 6 | 13 | |
| Female | 19 | 9 | 7 | |
| Tumor location | 0.296 | |||
| Upper extremity | 8 | 0 | 8 | |
| Lower extremity | 25 | 14 | 11 | |
| Trunk | 2 | 1 | 1 | |
| Tumor size (cm) | 0.244 | |||
| ≤10 | 26 | 13 | 13 | |
| >10 | 9 | 2 | 7 | |
| AJCC stage | 0.489 | |||
| Ⅱ | 23 | 11 | 12 | |
| Ⅲ | 11 | 4 | 7 | |
| IV | 1 | 0 | 1 | |
| Histological diagnosis | 0.696 | |||
| UPS | 27 | 11 | 16 | |
| High-grade myxofibrosarcoma | 5 | 3 | 2 | |
| Leiomyosarcoma | 2 | 1 | 1 | |
| Rhabdomyosarcoma | 1 | 0 | 1 |
Groups: Good prognosis, alive at last follow-up visit; poor prognosis, died of disease during the follow-up period (mean, 69.1 months; range, 4-150 months). SD, standard deviation; UPS, undifferentiated pleomorphic sarcoma; AJCC, American Joint Committee on Cancer.